Advertisement
Australia markets closed

  • ALL ORDS

    7,817.40
    -81.50 (-1.03%)
     

  • ASX 200

    7,567.30
    -74.80 (-0.98%)
     

  • AUD/USD

    0.6424
    -0.0001 (-0.02%)
     

  • OIL

    83.14
    +0.41 (+0.50%)
     

  • GOLD

    2,397.50
    -0.50 (-0.02%)
     

  • Bitcoin AUD

    101,120.45
    +5,296.37 (+5.53%)
     

  • CMC Crypto 200

    1,333.13
    +20.50 (+1.59%)
     

  • AUD/EUR

    0.6022
    -0.0009 (-0.15%)
     

  • AUD/NZD

    1.0891
    +0.0016 (+0.14%)
     

  • NZX 50

    11,796.21
    -39.83 (-0.34%)
     

  • NASDAQ

    17,394.31
    -99.31 (-0.57%)
     

  • FTSE

    7,835.61
    -41.44 (-0.53%)
     

  • Dow Jones

    37,775.38
    +22.07 (+0.06%)
     

  • DAX

    17,718.51
    -118.89 (-0.67%)
     

  • Hang Seng

    16,224.14
    -161.73 (-0.99%)
     

  • NIKKEI 225

    37,068.35
    -1,011.35 (-2.66%)
     

Better RSV Vaccine Stock: Pfizer, GSK, or Moderna?

Jim Halley, The Motley Fool
·5-min read
Better RSV Vaccine Stock: Pfizer, GSK, or Moderna?

No vaccine has been approved to prevent respiratory syncytial virus (RSV), but there are more than 30 different RSV vaccine candidates in clinical trials, according to PATH, a global health organization. Research from the Centers for Disease Control and Prevention (CDC) estimate that between 60,000 and 160,000 adults 65 and older are hospitalized each year with RSV, and 6,000 to 10,000 older adults die because of it. One to two out of every 100 children younger than 6 months of age with an RSV infection may need to be hospitalized.

Continue reading